Sign in
Active, not recruitingEarly phase 1

PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging

Key facts

Who runs it
The First Affiliated Hospital of Soochow University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
30 people, planned
Started
24 Sept 2026
Expected to end
24 Sept 2028
Type of study
Interventional, 2 groups
Treatments tested
  • 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging
  • 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging
Record updated
12 November 2026

Who can take part

Age
18 years to 80 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Voluntary provision of written informed consent; Male, aged 18-80 years; Pathologically confirmed prostate cancer, including newly diagnosed disease, recurrence after surgery, or metastatic disease; At least one measurable or evaluable lesion; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Hematological parameters, liver and kidney function, and electrolyte levels meeting protocol-defined requirements; Ability to cooperate with and complete PET/CT imaging

Who cannot take part

  • Inability to tolerate or cooperate with PET/CT imaging, for example, due to claustrophobia; Severe, uncontrolled disease affecting vital organs, including the heart, liver, or kidneys; Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will evaluate the diagnostic performance and safety of gallium-68 (68Ga)-labeled dual-target imaging agents in patients with prostate cancer. These investigational agents are designed to target either EphA2 and prostate-specific membrane antigen (PSMA), or ACP3 and PSMA, for positron emission tomography/computed tomography (PET/CT) imaging.

Read full original descriptionShow less

The main aims are to assess how well these imaging agents detect prostate cancer lesions, evaluate their safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore their potential use in early diagnosis, determining the extent of cancer spread, and detecting cancer recurrence.

The 2 groups in the trial

  • 68Ga-Labeled EphA2/PSMA Dual-Target PET/CT ImagingTreatment being tested

    Patients with prostate cancer will receive an intravenous injection of a 68Ga-labeled EphA2/PSMA dual-target radiotracer and undergo PET/CT imaging. Diagnostic performance, safety, biodistribution, and radiation dosimetry will be evaluated. Imaging findings will be compared with \[18F\]FDG PET/CT or single-target PSMA PET/CT findings according to the study protocol.

    Treatment: 68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging

  • 68Ga-Labeled ACP3/PSMA Dual-Target PET/CT ImagingTreatment being tested

    Patients with prostate cancer will receive an intravenous injection of a 68Ga-labeled ACP3/PSMA dual-target radiotracer and undergo PET/CT imaging. Diagnostic performance, safety, biodistribution, and radiation dosimetry will be evaluated. Imaging findings will be compared with \[18F\]FDG PET/CT or single-target PSMA PET/CT findings according to the study protocol.

    Treatment: 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Clinical Study Evaluating the Diagnostic Performance and Safety of PSMA-Targeting Dual-Target Radiopharmaceuticals in Patients With Prostate Cancer
Record updated
12 November 2026